CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 37 enrolled
Drug / intervention
Baktar 800mg h.s. +1 moredrug
Likely dose
Baktar 800mg h.s.from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01800799
NCT01800799N/ACompleted
CompareCT.gov

Use of Urinary Nerve Growth Factor as A Biomarker to Determine Complete Resolution of Bladder Inflammation After Acute Bacterial Cystitis in Women

Buddhist Tzu Chi General Hospital·interventional·Posted Feb 28, 2013·Updated Feb 17, 2017

In Brief

A clinical study evaluating Baktar 800mg h.s. and Celecoxib 200mg QD for Urinary Tract Infection. Completed, enrolled 37 participants across 1 site.

Detailed Summary

This study will enroll 30 female patients with the first time urinary tract infection (UTI), 30 female patients with recurrent UTI and 10 female without any prior history of UTI or urinary tract pathology will be invited to serve as the controls. Urine samples will be collected in the patients at baseline, 7 days after antibiotics treatment, and 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Urinalysis will be performed at each visit and urine culture will be performed at baseline and at the 2 weeks and 3 months visits. Urine samples at baseline and 3 months will be collected from the controls for comparison.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Tract Infection
CountriesTaiwan
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 28, 2013
Enrollment StartFeb 1, 2013
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.3 years ago

Interventions

Baktar 800mg h.s.drug

Antimicrobial agent (Baktar 800mg h.s.)

Celecoxib 200mg QDdrug

Anti-inflammatory agent (Celecoxib 200mg QD)